Blue Orbit is the latest addition to AdvoCare’s portfolio of innovative, science-backed products, aimed at helping individuals achieve optimal well-being and address a wide variety of modern-day wellness needs.
Comparable sales increased 2.0 percent in the second quarter, reflecting a comparable store sales increase of 0.7 percent and a comparable digital sales increase of 8.7 percent. Comp sales growth was driven by a 3 per cent increase in traffic.
The journals are part of the Caliber Fashion Artist Series, a line within the Caliber store brand of school, work and stationery products.
This potential partnership aims to bring together Kainomyx’s expertise in novel drug discovery.
New facility opening in Walton Hills demonstrates ongoing commitment to increase U.S. warehouse capacity and modernize operations.
81% of evening meals are sourced from the comfort of home
80% of Americans admit they aren’t sure if they have a first-degree relative with colorectal cancer, emphasizing the need for increased education to facilitate early screening.
Genoa pharmacists complete Mental Health First Aid training to play a critical role in recognizing and addressing mental health issues.
M&M'S Ice Cream Cookie Sandwiches and GREENIES™ Dental Treats for Dogs help pet parents and their canine companions beat the summer heat.
The clinic offers personalized care to the community while providing immediate pharmacist treatment for minor illnesses, as well as services including chronic disease management, vaccinations, men’s and women’s health, and point-of-care testing, among others.
PLMA’s 'The Store Brands Phenomenon 2024' Private Label Trade Show will be held Nov. 17-19 in Chicago.
She has nearly 20 years of retail grocery experience spanning nearly all areas of the business.
The partnership will utilize Walgreens’s clinical trial ecosystem.
Trust is crucial for achieving customer loyalty and repeat purchases, as well as creating brand evangelists, and authenticity is a cornerstone of building consumer trust.
The recent release of an interim report by the Federal Trade Commission about what the agency characterizes as “prescription drug middlemen” represents a vindication of sorts for pharmacy advocates who have long contended that PBMs employ business practices that skew the market to their advantage.
